Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation.

Published on May 1, 2020in Clinical Gastroenterology and Hepatology8.549
· DOI :10.1016/J.CGH.2019.07.007
Christopher J Black13
Estimated H-index: 13
(University of Leeds),
Nicholas E Burr14
Estimated H-index: 14
(University of Leeds),
Alexander C. Ford86
Estimated H-index: 86
(University of Leeds)
Sources
Abstract
: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder affecting 1 in 10 people and associated with poor psychological health, reduced quality of life, and increased health care expenditure.1 The etiology is complex and incompletely understood.2 Approximately one-third of patients have IBS with constipation (IBS-C),1 for which there are licensed therapies available in the United States. We summarized comparative efficacy of these in a recent network meta-analysis of randomized controlled trials (RCTs).3 Tegaserod, a 5-hydroxytryptamine-4 receptor agonist, approved by the Food and Drug Administration (FDA) for IBS-C, was withdrawn in 2007 after a small excess number of cerebrovascular and cardiovascular ischemic events in patients taking the drug.4 However, since our network meta-analysis, it has been reintroduced in the United States. It is therefore important to understand its efficacy relative to other available licensed therapies for IBS-C.
📖 Papers frequently viewed together
3 Authors (Lin Chang, ..., Shahnaz Sultan)
89 Citations
9 Citations
References5
Newest
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
Background & Aims Several secretagogues have been approved for the treatment of irritable bowel syndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C. Methods We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane Central Register of Controlled Trials through June 2018 to identify randomized controlled trial...
68 CitationsSource
#1Gerald Holtmann (UQ: University of Queensland)H-Index: 73
#2Alexander C. Ford (University of Leeds)H-Index: 86
Last. Nicholas J. Talley (University of Newcastle)H-Index: 183
view all 3 authors...
Summary Traditionally, irritable bowel syndrome has been considered to be a disorder with no known underlying structural or biochemical explanation, but this concept is likely to be outdated. In this Review we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain–gut disorder. There is epidemiological evidence that, in a major subset of patients, gastrointestinal symptoms arise first and only later do incident mood disorders occur. Additionally, possible mechan...
162 CitationsSource
#1Rebecca M. Lovell (St James's University Hospital)H-Index: 3
#2Alexander C. Ford (University of Leeds)H-Index: 86
Background & Aims Many cross-sectional surveys have reported the prevalence of irritable bowel syndrome (IBS), but there have been no recent systematic review of data from all studies to determine its global prevalence and risk factors. Methods MEDLINE, EMBASE, and EMBASE Classic were searched (until October 2011) to identify population-based studies that reported the prevalence of IBS in adults (≥15 years old); IBS was defined by using specific symptom-based criteria or questionnaires. The prev...
1,135 CitationsSource
#1J. NovickH-Index: 1
#2P. MinerH-Index: 1
Last. Martin Lefkowitz (Novartis)H-Index: 56
view all 8 authors...
Summary Background : Irritable bowel syndrome is a common functional gastrointestinal disorder which affects up to 20% of the population, with a predominance in females. Aim : To evaluate the efficacy and safety of tegaserod in female patients with irritable bowel syndrome characterized by symptoms of abdominal pain/discomfort and constipation. Methods : In a randomized, double-blind, multicentre study, 1519 women received either tegaserod, 6 mg b.d. (n = 767), or placebo (n = 752) for 12 weeks,...
272 CitationsSource
#2I. FumagalliH-Index: 1
Last. P. Rüegg (Novartis)H-Index: 1
view all 7 authors...
Aim: To investigate the efficacy and safety of tegaserod, a novel 5-HT4 receptor partial agonist, in a randomized, double-blind, placebo-controlled, 12-week treatment, multicentre study. Methods: Eight hundred and eighty-one patients with irritable bowel syndrome, characterized by abdominal pain, bloating and constipation, received tegaserod, 2 mg b.d. or 6 mg b.d., or placebo for 12 weeks. Results: Tegaserod, 2 mg b.d. and 6 mg b.d., showed a statistically significant relief of overall irritabl...
435 CitationsSource
Cited By26
Newest
#1Joy J. Liu (NU: Northwestern University)
#2Darren M. Brenner (NU: Northwestern University)H-Index: 17
Irritable bowel syndrome with constipation is a common disorder that significantly impairs quality of life. There are now multiple classes of therapeutics that have been shown via rigorous clinical testing to improve the abdominal and bowel symptoms attributed to irritable bowel syndrome with constipation. These include the secretagogues (lubiprostone, linaclotide, plecanatide, tenapenor) and the prokinetic agent tegaserod. This article highlights the pivotal evidence for these agents and most r...
Source
#1Christopher J Black (University of Leeds)H-Index: 13
#2Heidi M Staudacher (Deakin University)H-Index: 20
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
Objective null A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) is recommended for irritable bowel syndrome (IBS), if general lifestyle and dietary advice fails. However, although the impact of a low FODMAP diet on individual IBS symptoms has been examined in some randomised controlled trials (RCTs), there has been no recent systematic assessment, and individual trials have studied numerous alternative or control interventions, meaning the best com...
Source
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Ciaran Judge (St James's University Hospital)H-Index: 1
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Summary null Background null Functional constipation is a common functional bowel disorder in the community, which has a varying prevalence across cross-sectional surveys. We did a contemporaneous systematic review and meta-analysis of studies using comparable methodology and all iterations of the Rome criteria to estimate the global prevalence of functional constipation. null Methods null In this systematic review and meta-analysis, we searched MEDLINE, Embase, and Embase Classic from Jan 1, 19...
1 CitationsSource
#1Alfred D. Nelson (Mayo Clinic)H-Index: 10
#2Christopher J Black (St James's University Hospital)H-Index: 13
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
BACKGROUND Although bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS-C), treatment is empirical with no specific guidelines for its management. AIM To conduct a pairwise and network meta-analysis, using a frequentist approach, of Food and Drug Administration-licensed drugs for IBS-C comparing their efficacy for abdominal bloating as a specific endpoint. METHODS We searched the medical literature through December 2020 to identify randomised...
2 CitationsSource
#1Dipesh H. Vasant (University of Manchester)H-Index: 10
#2Peter Paine (University of Salford)H-Index: 15
Last. Alexander C. Ford (St James's University Hospital)H-Index: 86
view all 13 authors...
Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new ev...
4 CitationsSource
#1Eric D. Shah (Dartmouth–Hitchcock Medical Center)H-Index: 8
#2Darren M. Brenner (NU: Northwestern University)H-Index: 17
Last. Vincent L. ChenH-Index: 14
view all 3 authors...
BACKGROUND Effective prescription drug treatment of constipation-predominant irritable bowel syndrome (IBS-C) requires patients to remain on daily therapy, yet predictive factors to optimize treatment selection are unknown. AIMS We assessed whether common comorbidities including chronic overlapping pain conditions (COPCs), mood disorders, or concurrent medications influence the risk of discontinuing IBS-C prescription drug therapy. METHODS We included all IBS-C patients who initiated treatment w...
Source
#1Christopher J Black (University of Leeds)H-Index: 13
#2Yan Yiannakou (County Durham and Darlington NHS Foundation Trust)H-Index: 13
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
BACKGROUND Conventionally, irritable bowel syndrome (IBS) is subgrouped using predominant stool form, yet it is a complex disorder, with multiple biopsychosocial contributors. We previously derived and validated a latent class model subgrouping people with IBS into seven clusters based on gastrointestinal and extraintestinal symptoms and psychological profile. AIMS To conduct longitudinal follow-up examining the natural history and prognostic value of these clusters. METHODS Participants complet...
3 CitationsSource
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Ciaran Judge (St James's University Hospital)H-Index: 1
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Background: Chronic idiopathic constipation (CIC) is a common functional bowel disorder in the community, whose prevalence varies across cross-sectional surveys. We performed a contemporaneous systematic review of studies using comparable methodology, and all iterations of the Rome criteria, to estimate global prevalence. Methods: MEDLINE, EMBASE, and EMBASE Classic were searched (from 1990 to December 2020) to identify population-based studies reporting the prevalence of CIC in adults (≥18 year...
Source
#1Michael Camilleri (Mayo Clinic)H-Index: 146
Importance The prevalence of irritable bowel syndrome (IBS) in the United States is between 7% and 16%, most common in women and young people, with annual direct costs estimated at more than $1 billion dollars in the United States. Traditionally, the diagnosis of IBS has been based on the positive identification of symptoms that correlate with several different syndromes associated with disorders such as IBS diarrhea, IBS constipation, functional diarrhea, functional constipation, chronic functi...
6 CitationsSource
#1Shin Fukudo (Tohoku University)H-Index: 54
#2Masatoshi NakamuraH-Index: 1
Last. Hiroto Miwa (Hyogo College of Medicine)H-Index: 54
view all 5 authors...
Abstract Background and aims Treatment options for irritable bowel syndrome with constipation (IBS-C) are limited—new prokinetic drugs are needed. We evaluated the efficacy and safety of minesapride (DSP-6952), a partial agonist with high affinity for 5-HT4 receptors, in patients with IBS-C in Japan. Methods We performed a double-blind phase 2 study of 171 patients with Rome III-defined IBS-C at 33 centers in Japan, from December 2012 through August 2013. Patients were randomly assigned to group...
7 CitationsSource